Since late 2019, the new SARS-CoV-2 virus belonging to the Coronaviridae family has been
responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral …

Effective treatments specific for COVID-19 are still lacking. In the setting of passive
immunotherapies based on neutralizing antibodies (nAbs), randomized controlled trials of …

ABSTRACT Hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-
CoV-2 convalescent plasma (CP) are under evaluation in several clinical trials of …

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), appeared in December 2019 in Wuhan, China and is now a …

Since the very beginning of the COVID-19 pandemic, different treatment strategies have
been explored. These mainly involve the development of antimicrobial, antiviral, and/or anti …

In the absence of an effective vaccine or monoclonal therapeutic, transfer of convalescent
plasma (CCP) was proposed early in the SARS-CoV-2 pandemic as an easily accessible …

The COVID-19 therapeutic landscape rapidly evolved throughout the course of the SARS-
CoV-2 pandemic. However, the ingenuity of our community quickly coalesced to identify …

Introduction: Severe acute respiratory syndrome causing coronavirus SARS-CoV-2
(coronavirus disease 2019 (COVID-19)) has recently resulted in the recent global pandemic …

The emergence and dissemination of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) and the resulting COVID-19 pandemic triggered a global public health crisis …

Summary Hyperimmune immunoglobulin (hCoV-2IG) generated from SARS-CoV-2
convalescent plasma (CP) are under evaluation in clinical trials. Here we explored the …